[KEYNOTE-426 : Axitinib plus pembrolizumab vs sunitinib in the first-line treatment of metastatic renal cell carcinoma].
[KEYNOTE-426 : Axitinib plus pembrolizumab vs sunitinib in the first-line treatment of metastatic renal cell carcinoma].
Urologe A. 2020 May 26;:
Authors: Bedke J, Stühler V
PMID: 32458147 [PubMed - as supplied by publisher]
Source: Der Urologe. Ausg. A - Category: Urology & Nephrology Authors: Bedke J, Stühler V Tags: Urologe A Source Type: research
More News: Cancer & Oncology | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology